Kaye Scholer Advises Novartis in Collaboration Agreement with MolecularMD

February 19, 2014

Kaye Scholer advised longtime client Novartis in a collaboration agreement with MolecularMD Corporation to develop a companion diagnostic test to aid in the identification of Ph+ chronic myelogenous leukemia (CML) patients who have achieved durable minimal residual disease with nilotinib (Tasigna®), and to provide molecular monitoring for patients during treatment-free remission. MolecularMD Corporation is a private company that develops and commercializes specialty molecular diagnostics for oncology applications.

The Kaye Scholer team advising Novartis was led by Counsel Aaron Gardner with assistance from Partner Andres Liivak.


Email Disclaimer